Sign inJoin waitlistJoin the waitlist

Lynda Vrooman

Clinical Program Leader, Pediatric Survivorship Program · Mass General Brigham

Credentials: · · ·

History

Mass General Brigham
Present

Pediatric Hematology Oncology
Boston Children's Hospital
2005–2008
Pediatrics
Boston Children's Hospital
2002–2005
Harvard Medical School
1998–2002

Research

Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic…
Journal of Clinical Oncology · 2013 · First of 19 authors · Corresponding · 267 citations
Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a…
The Lancet Oncology · 2015 · 208 citations
Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation
Haematologica · 2016 · 190 citations

Lewis Silverman
31 papers
Stephen Sallan
16 papers
Andrew Place
13 papers
Kara Kelly
13 papers
Barbara Asselin
12 papers
Peter Cole
10 papers
LC
Luis Clavell
9 papers
MS
Marshall Schorin
9 papers
Steven Lipshultz
9 papers
Jennifer Welch
7 papers
Lisa Kenney
7 papers
CR
Christopher Recklitis
6 papers

Clinical trials

Bone Mineral Density Status in Pediatric and Adolescent Survivors of Childhood Cancer With History of Bone Fracture
Principal investigator · Completed
Dana-Farber Cancer Institute
2015–2024
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
Principal investigator · Completed · Phase 2
Jazz Pharmaceuticals
2012–2013
05-001: Treatment of Acute Lymphoblastic Leukemia in Children
Principal investigator · Completed · Phase 3
Dana-Farber Cancer Institute
2005–2019
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
Site PI · Recruiting
Children's Oncology Group
2014–2026